Rein Therapeutics Q4 Adj. EPS $(0.11) Beats $(0.24) Estimate

Rein Therapeutics (NASDAQ:RNTX) reported a Q4 adjusted EPS of $(0.11), surpassing the analyst estimate of $(0.24) by 54.17%. This represents a significant improvement, with losses decreasing by 94.18% compared to $(1.89) per share in the same quarter last year.